Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

CTA fund of funds FRM Sigma gains momentum as assets approach $1 billion

Friday, June 10, 2011
FRM Sigma, the CTA fund of funds managed by Financial Risk Management (FRM), continues to build momentum as one of the leading and most compelling ways for investors to access CTA returns.

The fund has been gaining increasing traction with investors, with assets doubling in the last twelve months, reaching nearly $700 million at the end of April 2011. Based on the current rate of inflows, Sigma is projected to reach $1 billion in assets by the end of 2011.

In addition, on 26 May, Sigma was named best 'Fund of Hedge Funds Sector Specialist over $500m’ at the HFMWeek European Performance Awards. This is the second time in three years that Sigma has won the sector specialist category.

Over its five year track record, Sigma has consistently demonstrated its ability to outperform other CTA funds of funds as well as many premier single manager CTAs. Since inception in November 2005, Sigma has generated total net returns of over 103%, including a net return of 17.5% in 2010 and 36.4% in 2008.

Marc Fisher, Managing Director at FRM, stated: “Sigma’s outperformance is directly linked to our distinctive approach. The fund performs more like a premier CTA than a traditional fund of funds.”

“We comprehensively evaluate the CTA universe to find the best advisors and invest in an active basket of these CTAs using managed accounts. This provides transparency, liquidity and control, and allows us to dynamically adjust allocations to maximise performance.

“Sigma helps give CTA investors peace of mind. It targets the performance of a world-class single CTA, but mitigates many of the risks of investing with a single CTA.”

(press release)

Source

kb

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for